February 2015, Vol 4, No 1

← Back to Issue

Enthusiasm Mounts in the Personalized Medicine Movement

Letter to Our Readers

Dear Colleague,

It is my pleasure to welcome you to the 2015 volume of Personalized Medicine in Oncology (PMO). We are extremely enthusiastic about the forthcoming, much anticipated advances in the personalized medicine movement this year. And we’re not the only ones. Of course, those of us in the oncology community are acutely aware of the vast amount of research that has gone into establishing personalized medicine as the goal of oncology care, but now the nation at large has become aware of the promise of personalized medicine too, as exemplified even in the president’s State of the Union address last month.

More than ever, we are marching toward a future where the combination of past progress and current technologies promises to advance our ability to provide the most effective, including cost-effective, care for our patients with cancer. All of which are reflected in our pages. This year, you will note the following in PMO:

  • Interview with the Innovators 2015 series: We will present eye-opening, provocative, and informative interviews with those who are shaping the landscape of personalized care in oncology
  • Innovator of the Year award: Meet the current Innovator of the Year, recognized by PMO for his incredible contributions to the personalized medicine movement
  • Personalized Medicine Coalition (PMC): Our collaboration with PMC continues with the column by Dr Edward Abrahams, The Last Word

In addition, we are delighted to announce a 2015 volume of our sister publication, Immunotherapy in Oncology, to specifically cover advances in this timely and exciting realm of oncology.

Thank you for sharing our enthusiasm in the quest to personalize care by being part of our reading community. We are looking forward to a bright future in which we are able to improve the lives of our patients.


Coeditor in Chief
Personalized Medicine in Oncology

Uncategorized - February 19, 2015

Case Report: Intense Maintenance in a Woman with High-Risk Multiple Myeloma

Tremendous progress has been made in the treatment of patients with multiple myeloma (MM) over the past 2 decades. The 5-year relative survival ratio increased from 26.3% in 1975 to 45.1% in 2006, when only 3 drugs were approved for the treatment of MM. The arsenal of drugs approved by [ Read More ]

Uncategorized - February 19, 2015

Genomic Panel Likely to Be Cost-effective in AML

Genomic sequencing methods are likely to be more cost-effective than stepwise addition of single mutational testing in patients with intermediate-risk acute myeloid leukemia (AML), found Sonya Cressman, PhD, a health economist at the Canadian Centre for Applied Research in Cancer Control, Vancouver. “Genomic sequencing costs have decreased in recent years [ Read More ]